Jim Cramer on Catalyst Pharmaceuticals: “It’s a Very Inexpensive Stock”

Group 1 - Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is recognized for providing treatments for rare conditions such as Lambert-Eaton myasthenic syndrome and Duchenne muscular dystrophy [1] - The company reported earnings of 70 cents per share, exceeding the expected 55 cents, indicating strong financial performance [1] - Despite a positive outlook from Jim Cramer, the stock has experienced a decline of approximately 13% since the comments were made [1] Group 2 - There is a belief that certain AI stocks may offer greater upside potential compared to CPRX, suggesting a competitive investment landscape [2]